Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (101-110 of 204) with videos related to

Pageof 21
Sort By:
Tuberculosis (Edinburgh, Scotland)|October 9, 2022
Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteriaPrem Shankar, Sanjay Singh, Gunavanthi D Boorgula, et al.
Tuberculosis (Edinburgh, Scotland)|December 13, 2022
Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasiiGunavanthi D Boorgula, Sanjay Singh, Prem Shankar, et al.
The Journal of Infectious Diseases|August 1, 2013
Serum drug concentrations predictive of pulmonary tuberculosis outcomesJotam G Pasipanodya, Helen McIlleron, André Burger, et al.
Scandinavian Journal of Infectious Diseases|February 13, 2003
Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenonTawanda Gumbo, Roy F Chemaly, Carlos M Isada, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2023
Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so farSanjay Singh, Gunavanthi D Boorgula, Santosh Aryal, et al.
Frontiers in Pharmacology|May 3, 2021
Comparison of Rifamycins for Efficacy Against <i>Mycobacterium avium</i> Complex and Resistance Emergence in the Hollow Fiber Model SystemGunavanthi D Boorgula, Laxmi U M R Jakkula, Tawanda Gumbo, et al.
Antimicrobial Agents and Chemotherapy|November 24, 2005
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activityArnold Louie, Mark Deziel, Weiguo Liu, et al.
Antimicrobial Agents and Chemotherapy|July 27, 2016
Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of TuberculosisShashikant Srivastava, Chawanga Modongo, Chandima W Siyambalapitiyage Dona, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2022
Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable dosesMoti Chapagain, Jotam G Pasipanodya, Shruti Athale, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2016
A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the PlaygroundShashikant Srivastava, Devyani Deshpande, Jotam G Pasipanodya, et al.
Pageof 21

Showing results (101-110 of 204) with videos related to

Sort By:
Pageof 21
Tuberculosis (Edinburgh, Scotland)|October 9, 2022
Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteriaPrem Shankar, Sanjay Singh, Gunavanthi D Boorgula, et al.
Tuberculosis (Edinburgh, Scotland)|December 13, 2022
Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasiiGunavanthi D Boorgula, Sanjay Singh, Prem Shankar, et al.
The Journal of Infectious Diseases|August 1, 2013
Serum drug concentrations predictive of pulmonary tuberculosis outcomesJotam G Pasipanodya, Helen McIlleron, André Burger, et al.
Scandinavian Journal of Infectious Diseases|February 13, 2003
Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenonTawanda Gumbo, Roy F Chemaly, Carlos M Isada, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2023
Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so farSanjay Singh, Gunavanthi D Boorgula, Santosh Aryal, et al.
Frontiers in Pharmacology|May 3, 2021
Comparison of Rifamycins for Efficacy Against <i>Mycobacterium avium</i> Complex and Resistance Emergence in the Hollow Fiber Model SystemGunavanthi D Boorgula, Laxmi U M R Jakkula, Tawanda Gumbo, et al.
Antimicrobial Agents and Chemotherapy|November 24, 2005
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activityArnold Louie, Mark Deziel, Weiguo Liu, et al.
Antimicrobial Agents and Chemotherapy|July 27, 2016
Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of TuberculosisShashikant Srivastava, Chawanga Modongo, Chandima W Siyambalapitiyage Dona, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2022
Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable dosesMoti Chapagain, Jotam G Pasipanodya, Shruti Athale, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2016
A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the PlaygroundShashikant Srivastava, Devyani Deshpande, Jotam G Pasipanodya, et al.
Pageof 21